Table 3.
Endolysin and/or derivative | Phage | Antimicrobial spectrum | Enzymatic activity | Type of infection treated in vivo | Clinical trial phase | Clinical trials identifier/accession No | References |
---|---|---|---|---|---|---|---|
SAL200 | SAP-1 | S. aureus | Amidase and endopeptidase | Bacteremia | IIa | NCT03089697 | [61] |
Exebacase (CF-301 or PlySs2) | Prophage of S. suis | S. aureus, Streptococcus | Peptidase | Bacteremia | III | NCT04160468 | [28, 62] |
P128 | CHAP domain (TAME phage K) + SH3b (lysostaphin) | S. aureus | CHAP | Bacteremia | II | NCT01746654 | [96–98] |
Staphefekt SA.100 | M23 endopeptidase (lysostaphin) + Amidase (Ply2638) + SH3b (Ply2638) | S. aureus | Amidase and endopeptidase | Atopic dermatitis | I/II | NCT02840955 | [64, 99] |
Medolysin® | – | S. aureus | – | Bacterial wound infections | – | – | [100] |
XZ.700 | Staphefekt SA.100 deleted 44 amino acids region deleted | S. aureus | Amidase and endopeptidase | Skin infection | Pre-clinical | – | [64] |
MV-L | MR11 | S. aureus, S. simulans | Amidase and endopeptidase | Nares infection, sepsis | Pre-clinical | BAF33253 | [81] |
LysP108 | P108 | S. aureus | Amidase | Subcutaneous abscess | Pre-clinical | YP_009099525 | [17] |
80α | phi80α | S. aureus | Amidase and endopeptidase | Systemic infection | Pre-clinical | ABF71642 | [101] |
phi11 | phi11 | S. aureus | Amidase and endopeptidase | Systemic infection | Pre-clinical | YP_500516 | [101] |
LysK | K | S. aureus | Amidase and endopeptidase | Systemic infection | Pre-clinical | YP_024461 | [101] |
Ply2638 | 2638A | S. aureus | Amidase and endopeptidase | Systemic infection | Pre-clinical | AAX90995 | [101] |
Twort | Twort | S. aureus | Amidase and endopeptidase | Systemic infection | Pre-clinical | AAX92311 | [101] |
phiSH2 | phiSH2 prophage | S. aureus | Amidase and endopeptidase | Systemic infection | Pre-clinical | BAE05642 | [101] |
LysWMY | phiWMY | S. aureus | Amidase and endopeptidase | Systemic infection | Pre-clinical | BAD83402 | [101] |
CHAPK | K | S. aureus | Endopeptidase | Nasal infection | Pre-clinical | 4CT3_D | [18, 102] |
ClyF | CD domain (Ply187) + CBD domain (PlySs2) | S. aureus | CHAP | Bacteremia and burn wound infection | Pre-clinical | - | [22] |
LysSS | SS3e | S. aureus, Salmonella, Escherichia coli | – | Systemic infection | Pre-clinical | AAW51228 | [103] |
Ply6A3 | PD-6A3 | Acinetobacter baumannii, E. coli, S. aureus | – | Sepsis | Pre-clinical | ALM01856 | [104] |
gp144 | ΦKZ | Pseudomonas aeruginosa, S. aureus, E. coli, B. cereus | Transglycosylase | – | – | AAL83045 | [105] |
LysGH15 | GH15 | Staphylococcus | Amidase and CHAP | Bacteremia | Pre-clinical | ADG26756 | [26, 67, 106, 107] |
PlyGRCS | GRCS | S. aureus, S. epidermidis | Endopeptidase | – | – | AHJ10590 | [19] |
ClyH | CD domain (Ply187) + non-SH3b (phiNM3) | S. aureus | Amidase | Intraperitoneal infection | Pre-clinical | – | [108] |
MR-10 | MR-10 | S. aureus | – | Subcutaneous | Pre-clinical | – | [109, 110] |
LysH5 | PhiH5 | S. aureus, S. epidermidis | Amidase and endopeptidase | – | – | ACE77796 | [59, 68] |
ClyS |
CD domain (Twort) + CBD domain (phiNM3) |
S. aureus | Endopeptidase | Intraperitoneal, nasal and skin infection | Pre-clinical | – | [73, 78] |
ClyC | CD domain (Ply187) + CBD domain (LysSA97) | S. aureus | – | Bacteremia | Pre-clinical | – | [38] |
Lys16 | P68 | S. aureus | CHAP | – | – | AAO83890 | [101, 111] |
LysSAP33 | SAP33 | S. aureus | CHAP | – | – | QDH45454 | [42] |
Pal | Dp-1 | S. pneumoniae | Amidase | Nasopharyngeal infection | Pre-clinical | O03979 | [16] |
Cpl-1 | Cp1 | S. pneumoniae | Muramidase | Endocarditis, bacteremia, pneumonia, meningitis | Pre-clinical | NP_044837 | [69, 112–114] |
Cpl-7 | CP-7 | S. pneumoniae, S. pyogenes, E. faecalis | Muramidase | Embryo infection | Pre-clinical | P19385 | [115, 116] |
Cpl-711 | CD domain (Cpl-7) + CBD domain (Cpl-1) | S. pneumoniae | Muramidase | Bacteraemia | Pre-clinical | – | [117] |
PL3 | CD domain (Cpl-7) + CBD domain (LytA) | S. pneumoniae | Amidase | Embryo infection | Pre-clinical | – | [118] |
ClyJ |
CD domain (PlyC) + CBD domain (SPSL1) |
S. pneumoniae | CHAP | Bacteraemia | Pre-clinical | – | [119] |
ClyJ-3 | ClyJ variant | S. pneumoniae | CHAP | Bacteraemia | Pre-clinical | – | [120] |
ClyJ-3 m | ClyJ-3 variant | S. pneumoniae | CHAP | Bacteraemia | Pre-clinical | – | [121] |
23TH_48 | 23TH | S. pneumoniae | Amidase | – | – | QOI69927 | [122] |
MSlys | MS1 | S. pneumoniae | Amidase | – | – | AQY55407 | [123] |
PlyC | C1 | S. pyogenes | Amidase | Mucosal epithelium infection | Pre-clinical | AAP42310 | [76] |
PlyPy | MGAS5005 prophage | S. pyogenes | Endopeptidase | Bacteremia | Pre-clinical | AAM79913 | [124] |
PlyGBS | NCTC11261 | Group B streptococci, S. agalactiae | Endopeptidase and muramidase | Vaginal and oropharynx infection | Pre-clinical | AAR99416 | [74, 125] |
PlySK1249 | SK1249 prophage | S. agalactiae, Streptococcus dysgalactiae | Amidase and endopeptidase | Bacteremia | Pre-clinical | EGL49245 | [126] |
PlyG | γ-phage | B. anthracis, B. cereus | Amidase | Intraperitoneal infection | Pre-clinical | PFW40491 | [24] |
PlyPH |
B. anthracis BA2805 genome |
B. anthracis, B. cereus | – | Intraperitoneal infection | Pre-clinical | WP_098639153 | [127] |
LysPBC2 | PBC2 | B. cereus | Amidase | – | – | AKQ08512 | [128] |
PlyV12 | Φ1 | E. faecalis, E. faecium | Amidase | – | – | YP_009814814 | [70] |
LysEFm5 | IME-EFm5 | E. faecium | Amidase | – | – | YP_009200901 | [129] |
LysIME-EF1 | IME-EF1 | E. faecalis | Endopeptidase | Intraperitoneal infection | Pre-clinical | YP_009042672 | [126] |
LysEF-P10 | EF-P10 | E. faecalis | Endopeptidase | Balance of the gut microbiota | Pre-clinical | AQT27695 | [130] |
Ply3626 | phi3626 | C. perfringens | Amidase | – | – | NP_612849 | [131] |
Psa | St13 | C. perfringens | Amidase | – | – | WP_011010276 | [132] |
–, unknown or data not available